Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Clin Transl Sci. 2024 Mar;17(3):e13742. doi: 10.1111/cts.13742.
Clin Transl Sci. 2024.
PMID: 38494922
Free PMC article.
Clinical Trial.
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.
Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G.
Patnaik MM, et al. Among authors: pierola aa.
Leukemia. 2018 Nov;32(11):2512-2518. doi: 10.1038/s41375-018-0143-8. Epub 2018 Apr 25.
Leukemia. 2018.
PMID: 29749401
Free PMC article.
No abstract available.
Item in Clipboard
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G.
Montalban-Bravo G, et al. Among authors: pierola aa.
Oncotarget. 2018 Jan 3;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 9.
Oncotarget. 2018.
PMID: 29515765
Free PMC article.
Item in Clipboard
Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia.
Yang H, Fang Z, Wei Y, Bohannan ZS, Gañán-Gómez I, Pierola AA, Paradiso LJ, Iwamura H, Garcia-Manero G.
Yang H, et al. Among authors: pierola aa.
Leuk Res. 2017 Aug;59:85-92. doi: 10.1016/j.leukres.2017.05.016. Epub 2017 May 26.
Leuk Res. 2017.
PMID: 28599189
Item in Clipboard
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes C, Villar S, Ariceta B, Garcés JJ, Burgos L, Alignani D, Sarvide S, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo JL, Vidriales MB, Chillon C, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Pierola AA, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Paiva B, Montesinos P; PETHEMA cooperative study group.
Simoes C, et al. Among authors: pierola aa.
Br J Haematol. 2023 Jun;201(6):1239-1244. doi: 10.1111/bjh.18815. Epub 2023 Apr 14.
Br J Haematol. 2023.
PMID: 37057357
No abstract available.
Item in Clipboard
CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil.
Hungria V, Piérola AA, Filho JS, Crusoe E, Filho RJPM, Maiolino A, Rodríguez-Otero P.
Hungria V, et al. Among authors: pierola aa.
Hematol Transfus Cell Ther. 2023 Apr-Jun;45(2):266-274. doi: 10.1016/j.htct.2022.08.002. Epub 2022 Sep 20.
Hematol Transfus Cell Ther. 2023.
PMID: 36243623
Free PMC article.
Item in Clipboard
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C, Chillon MC, Martínez-Cuadrón D, Calasanz MJ, Vridiales MB, Vazquez I, Hernández-Ruano M, Ariceta B, Aguirre-Ruiz P, Burgos L, Alignani D, Sarvide S, Villar S, Pierola AA, Prosper F, Ayala R, Martínez-López J, Bergua Burgues JM, Vives S, Perez-Simon JA, Garcia-Fortes M, Bernal Del Castillo T, Colorado M, Olave M, Rodríguez-Gutiérrez JI, Labrador J, González M, San-Miguel JF, Sanz MÁ, Montesinos P, Paiva B.
Simoes C, et al. Among authors: pierola aa.
Blood Adv. 2023 Jan 10;7(1):167-173. doi: 10.1182/bloodadvances.2022008141.
Blood Adv. 2023.
PMID: 36240453
Free PMC article.
Item in Clipboard
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators.
Richardson PG, et al.
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
Lancet Oncol. 2019.
PMID: 31097405
Clinical Trial.
Item in Clipboard
Cite
Cite